Dustin Gable, MD, PhD, a pediatric neuromuscular neurologist at Johns Hopkins Medicine, discussed why bulbar dysfunction ...
Erika Trovato, DO, MS, program director of the Brain Injury Medicine Fellowship at Burke Rehabilitation Hospital, provided clinical advice for trainees and early-career physicians looking to establish ...
The absence of symptoms, nonserious classification, and generally stable neurodevelopmental assessments support short-term clinical quiescence, but do not define long-term neurologic risk. Uncertain ...
The FDA has granted Fast Track Designation to safusidenib, an investigational oral, brain-penetrant selective inhibitor of mutant IDH1, for the treatment of patients with IDH1-mutant glioma, according ...
The PDUFA date moved to November 22, 2026, because CBER accepted a major BLA amendment incorporating additional HOPE-3 follow ...
FDA has cleared C2N Diagnostics' PrecivityAD2 blood test for adults 40 years and older with cognitive symptoms, offering fast amyloid and tau insight to guide diagnosis and trials in Alzheimer disease ...
Despite meaningful advances in antithrombotic therapy over the past 2 decades, secondary stroke prevention remains an area of significant unmet need. Population aging, combined wi ...
A coalition of Charcot-Marie Tooth patient groups, clinicians, and pharma companies has published the first consensus framework for designing clinical trials in the disease. A coalition of ...
Continuing with FDA news, the FDA has granted Fast Track designation to remlifanserin (ACP-204; Acadia Pharmaceuticals), an ...
Episode 173 of the NeurologyLive ® Mind Moments ® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service. The Mind Moments podc ...
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by ...
AMO Pharma reached agreement with the FDA, UK MHRA, and Health Canada on the design of a registrational study of AMO-02 for congenital myotonic dystrophy type 1, which will use hospitalization as its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results